Predictive value of Galectin-3 in cognitive impairment: a systematic review and meta-analysis - Takeaways - MDSpire

Predictive value of Galectin-3 in cognitive impairment: a systematic review and meta-analysis

  • By

  • Ying-ying Yang

  • Xiao-xue Zeng

  • Xia He

  • Xia-lian Huang

  • Ming-xi Xu

  • Feng-le Mao

  • Yan-qiu Wang

  • Fu-li Qin

  • May 25, 2026

  • 0 min

Share

  • 1

    Cognitive impairment (CI) is a significant public health issue linked to aging, functional decline, and increased mortality risk.

  • 2

    Galectin-3 (Gal-3) is a biomarker associated with neuroinflammation and vascular injury, potentially useful for early CI prediction.

  • 3

    The meta-analysis included nine studies with 877 CI patients and 715 controls, showing significantly higher Gal-3 levels in the CI group.

  • 4

    Gal-3 levels were notably elevated in CI patients with vascular risk factors and those with mild cognitive impairment (MCI).

  • 5

    Further research is needed to clarify the role of Gal-3 in Alzheimer's disease, as current evidence does not support its significance.

Original Source(s)

Predictive value of Galectin-3 in cognitive impairment: a systematic review and meta-analysis

  • by Ying-ying Yang, Xiao-xue Zeng, Xia He, Xia-lian Huang, Ming-xi Xu, Feng-le Mao, Yan-qiu Wang, Fu-li Qin

  • May 25, 2026

Related Content

Structural Disadvantage in Adolescence and Biological Aging in Early Midlife

AI-driven insights into protein misfolding and innate immunity in neurodegenerative diseases

‘Are we just going to give up and die like every other generation?’